(Hepatocellular Carcinoma) Imfinzi + Tremelimumab Effective?
(Hepatocellular Carcinoma) Imfinzi + Tremelimumab Effective?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
(Hepatocellular Carcinoma) Imfinzi + Tremelimumab Effective?
- June 12, 2020
- Reading time 2 minutes
On May 29-31, 2020, Robin Kate Kelley presented at ASCO 2020 virtual conference: "Efficacy and safety results of anti-PD-L1 antibody Imfinzi (durvalumab) + anti-CTLA-4 antibody Tremelimumab in treatment-naive advanced hepatocellular carcinoma patients who have not used immune checkpoint inhibitors in Phase 2 clinical trial."
This Phase 2 clinical trial divided treatment-naive advanced hepatocellular carcinoma patients who have not used immune checkpoint inhibitors into four groups with primary endpoint safety and secondary endpoints overall survival, objective response rate, and duration of response:
- D + T300 group (4-week cycle, Imfinzi 1500mg + Tremelimumab 300mg, N=75 patients).
- D + T75 group (4-week cycle, Imfinzi 1500mg + Tremelimumab 75mg, N=84 patients).
- D group (4-week cycle, Imfinzi 1500mg, N=104 patients).
- T group (4-week cycle, Tremelimumab 750mg, N=69 patients).
In this trial, Grade 3-4 adverse event rates were: D + T300 group 35.1% / D + T75 group 24.4% / D group 17.8% / T group 42.0%. Treatment discontinuation rates due to adverse events: D + T300 group 10.8% / D + T75 group 6.1% / D group 7.9% / T group 11.6%.
Secondary endpoint median overall survival: D + T300 group 18.7 months / D + T75 group 11.3 months / D group 11.7 months / T group 17.1 months. Objective response rates: D + T300 group 22.7% / D + T75 group 9.5% / D group 9.6% / T group 7.2%. Median duration of response: D + T300 group not reached / D + T75 group 13.2 months / D group 14.8 months / T group 24.0 months.
Based on Phase 2 clinical trial results, Robin Kate Kelley concluded: Treatment-naive advanced hepatocellular carcinoma patients treated with anti-PD-L1 antibody Imfinzi + anti-CTLA-4 antibody Tremelimumab 300mg showed better anti-tumor efficacy compared to other groups, with manageable adverse events.
Note: The clinical trial data and medical information translated by "Medical Assistant" from overseas trials are not intended to promote participation in clinical trials or use of new drugs. Translation materials are for reference only, not as medication guidelines. Please consult healthcare professionals and refer to original content for accuracy.
Source: Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020 ASCO Virtual Scientific Program, Abstract No:4508)
-
Immunotherapy
-
Clinical Trial Drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase 2 Trial Results. (Lung Cancer) Non-Small Cell Lung Cancer with HER2 Gene Mutation: Effective with Enhertu? (Lung Cancer) Anti-B7-H3 Antibody DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4